CapsoVision Q2 FY26 operating loss widens to $7.58 million; revenue rises 10% to $3.6 million
CV•Q2 revenue rises, but losses widen
CapsoVision posted Q2 revenue of $3.6 million, up 10% year over year.
Operating loss widened to $7.58 million; net loss deepened to $7.48 million, or $(0.15) a share.
Margins and expenses under pressure
Gross margin fell 4 percentage points to 51% on selling-price pressure and higher customs and tariff costs.
Operating expenses climbed to $9.5 million, driven by colon pivotal-study spending, other trials, Canon engineering work, public-company costs, and stock-based compensation.
AI Highlights rollout and next steps
AI Highlights launched commercially in the EU; FDA clearance is expected by the end of Q3 2026, with a U.S. launch planned soon after.
